4
4Sc AG
XETRA:VSC
4Sc AG
XETRA:VSC
Price:
2.5
EUR
-16.11%
Market Cap:
€126.4m
Relative Value
There is not enough data to reliably calculate the relative value of VSC.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VSC
Relative Value
Base Case
Not Available
Multiples Across Competitors
VSC Competitors Multiples
4Sc AG Competitors
4Sc AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
4
|
4Sc AG
XETRA:VSC
|
126.4m EUR | 290 | -8.8 | -8.8 | -7.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 746 422.5 | -160 391.7 | -165 649.1 | -163 758.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.8B USD | 6.7 | 169.8 | 16.4 | 23.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.3B USD | 5.2 | 26.5 | 18.9 | 18.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
177.3B USD | 6.1 | 21.9 | 14.8 | 14.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120B USD | 10.2 | 32.6 | 24 | 25.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 087.6 | -532.7 | -682 | -663.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD | 5.5 | 17.6 | 14.9 | 17 | |
| AU |
|
CSL Ltd
ASX:CSL
|
86.7B AUD | 3.8 | 19.7 | 9.1 | 11.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 14.3 | 33.6 | 68 | 69.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.7 | -78.2 | -70.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
